Maravai LifeSciences (MRVI) Projected to Post Quarterly Earnings on Thursday

Posted by Francis Steltz on Jul 30th, 2026

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.05) per share and revenue of $48.6730 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.06. The business had revenue of $65.84 million for the quarter, compared to analysts’ expectations of $53.00 million. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%. On average, analysts expect Maravai LifeSciences to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Maravai LifeSciences Trading Down 3.9%

Shares of MRVI opened at $6.59 on Thursday. Maravai LifeSciences has a one year low of $1.99 and a one year high of $7.44. The stock has a 50-day moving average price of $5.71 and a 200 day moving average price of $4.26. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.96 and a current ratio of 5.91. The company has a market capitalization of $1.70 billion, a P/E ratio of -9.28 and a beta of 0.65.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Wells Fargo & Company upped their target price on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research report on Friday, May 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. UBS Group restated a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Wall Street Zen upgraded shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Finally, Weiss Ratings raised shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Check Out Our Latest Stock Analysis on Maravai LifeSciences

Insider Buying and Selling

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the completion of the sale, the general counsel directly owned 360,767 shares of the company’s stock, valued at $1,825,481.02. The trade was a 6.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.49% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of Maravai LifeSciences in the 4th quarter worth approximately $34,000. T. Rowe Price Investment Management Inc. raised its position in shares of Maravai LifeSciences by 2.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company’s stock valued at $20,595,000 after acquiring an additional 178,445 shares in the last quarter. Invesco Ltd. raised its position in shares of Maravai LifeSciences by 12.3% during the 4th quarter. Invesco Ltd. now owns 345,773 shares of the company’s stock valued at $1,124,000 after acquiring an additional 37,958 shares in the last quarter. Mackenzie Financial Corp lifted its stake in Maravai LifeSciences by 1.7% during the fourth quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company’s stock worth $20,148,000 after purchasing an additional 104,355 shares during the last quarter. Finally, Wellington Management Group LLP bought a new position in Maravai LifeSciences during the fourth quarter worth $7,670,000. Institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.